In an 83‑year‑old patient who was previously taking citalopram 30 mg daily, how should the medication be restarted, including appropriate initial dose and safety monitoring?

Restarting Citalopram in an 83-Year-Old Patient

In an 83-year-old patient previously on citalopram 30 mg daily, restart at 20 mg daily (not 30 mg) due to FDA-mandated maximum dose restrictions for patients over 60 years of age, with mandatory baseline ECG and electrolyte monitoring before initiation. 1

Critical Dose Limitation for Elderly Patients

The FDA drug label explicitly states that 20 mg/day is the maximum recommended dose for patients greater than 60 years of age due to higher drug exposures and increased risk of QT prolongation in this population 1. Your patient's previous dose of 30 mg daily exceeded safe limits and should not be resumed.

Why the Previous 30 mg Dose Was Unsafe

• Citalopram causes dose-dependent QTc prolongation, which has been associated with Torsade de Pointes, ventricular tachycardia, and sudden death 1
• Patients over 60 have higher citalopram exposures, making them more vulnerable to cardiac complications 1
• The 2012 FDA boxed warning specifically prohibits doses >20 mg/day in adults older than 60 years 2

Pre-Restart Cardiac Risk Assessment

Before restarting citalopram, you must perform:

Mandatory baseline evaluation:

• ECG to assess QTc interval and identify conduction abnormalities
• Serum potassium and magnesium levels
• Review all current medications for QTc-prolonging drugs or drug interactions
• Assess for cardiac history: chest pain, dyspnea, palpitations, syncope, or family history of sudden cardiac death 3

Contraindications to restarting (do not prescribe if present):

• Congenital long QT syndrome
• Recent acute myocardial infarction
• Uncompensated heart failure
• Bradycardia
• Uncorrected hypokalemia or hypomagnesemia
• Concurrent use of other QTc-prolonging medications (Class IA/III antiarrhythmics, certain antipsychotics, antibiotics like moxifloxacin) 1

Restart Protocol

Initial dose: 20 mg once daily (morning or evening, with or without food) 1

Follow-up monitoring:

• Repeat ECG within 1-2 weeks after initiation (at steady state, approximately 5 half-lives) 3
• Monitor for symptoms: palpitations, syncope, near-syncope, or new cardiac symptoms
• Discontinue immediately if QTc >500 ms or increase >60 ms from baseline 3, 1

Do not increase the dose: The 20 mg maximum is absolute for this age group—no titration to higher doses is permitted 1

Additional Safety Considerations in the Elderly

Hyponatremia Risk

Elderly patients have significantly elevated risk of SSRI-induced hyponatremia (0.5-12% in older adults, OR 3.3 compared to other drug classes), typically occurring within the first month 2. Monitor sodium levels at baseline and if symptoms of confusion, weakness, or altered mental status develop 4.

Drug Interactions

Review all medications for:

• CYP2C19 inhibitors (e.g., cimetidine, omeprazole)—these further limit maximum dose to 20 mg/day 1
• Other QTc-prolonging agents—absolute contraindication to citalopram use 1
• Antiplatelet agents or NSAIDs—increased gastrointestinal bleeding risk (OR 1.2-1.5) 2

Monitoring for Clinical Worsening

During the first few months, monitor closely for:

• Worsening depression or suicidal ideation (though risk is protective in patients ≥65 years: OR 0.06) 1
• Agitation, anxiety, panic attacks, insomnia, irritability, hostility, or akathisia 1
• Serotonin syndrome symptoms if restarting after interruption: hyperthermia, myoclonus, hyperreflexia, altered consciousness 5

Common Pitfalls to Avoid

1. Do not resume the previous 30 mg dose—this violates FDA safety guidelines and substantially increases cardiac risk in elderly patients
2. Do not skip baseline ECG and electrolytes—these are essential for risk stratification given the patient's age
3. Do not restart abruptly after prolonged discontinuation—while the standard restart dose is 20 mg, be vigilant for serotonin syndrome in the first days to weeks, particularly in elderly patients with compromised physiologic reserve 5
4. Do not combine with other QTc-prolonging medications—this is an absolute contraindication 1

Duration of Treatment

If restarting for maintenance therapy, depression typically requires several months or longer of sustained treatment. Efficacy has been demonstrated for up to 32 weeks total (including acute and maintenance phases) 1. However, the dose must remain at 20 mg/day maximum throughout treatment in this 83-year-old patient.